ZhuoDao Medical Completes Series B Financing Led by Danlu Capital, Hengxu Capital, and Shunwei Capital to Advance Intelligent Rehabilitation Solutions

Recently, Zhuodao Medical, a Chinese enterprise specializing in rehabilitation robotics and innovative intelligent rehabilitation solutions^®Announces Completion of Series B Financing, Co-Led by Danlu Capital and Hengxu Capital, with Shunwei Capital Participating; Total Investment Exceeds RMB 100 Million. This Round of Financing Will Accelerate ZD Medical’s^®Work on innovative R&D, market access, and large-scale implementation in the field of comprehensive intelligent rehabilitation solutions.

ZD Medical^®Established in 2015, it is a Shanghai-based high-tech enterprise dedicated to the research and development and industrialization of high-end rehabilitation robots and intelligent comprehensive rehabilitation solutions. The company boasts a team of over 100 members,The core team possesses over a decade of experience in the R&D of rehabilitation robots and medical device project management. Leveraging a systematic, framework-based, multidisciplinary integrated technology platform for rehabilitation robotics, our developed rehabilitation robots have been installed and applied in nearly 1,000 hospitals and institutions across China.Shanghai ZD Medical Technology Co., Ltd. has undertaken the National Key R&D Program and the Shanghai Science and Technology Innovation Plan dozens of times cumulatively, and is a drafting entity for the national standards on upper-limb rehabilitation training robots.^®Committed to the digital upgrading and intelligent transformation of the traditional rehabilitation industry, it has gradually grown into a leading high-tech enterprise with a global perspective and significant industry influence.

ZD Medical^®Founder Wang Daoyu stated, “As an innovative medical device company independently developing solutions in the rehabilitation field, it is a privilege to encounter investors who truly understand our vision during the lengthy process of product development and commercialization. We are delighted to have gained the recognition of our new shareholders. We thank them for their steadfast support of the ZD Medical project during the pandemic, and we also extend our gratitude to our existing shareholders for their years of trust and warmth. As population aging accelerates, we believe that the ZD Medical team, with an average age of under 30, will cherish the opportunities presented by this era and embrace the mission entrusted to our generation. After eight years of persistent effort behind the scenes, we remain passionate and sincerely committed to technological innovation in rehabilitation, striving to develop more high-quality products and serve more patients. We believe this round of financing will significantly accelerate the commercialization of our innovative products and solutions, and we look forward to becoming a first-class intelligent rehabilitation enterprise in China and a global leader at the earliest opportunity.”

Lu Qinchao, Founding and Managing Partner of Danlu Capital, the lead investor in this round, stated: “The field of rehabilitation robotics encompasses a wide range of disciplines, including rehabilitation medicine, biomechanics, mechanical engineering, electronics, materials science, computer science, and robotics. Its research findings can be broadly applied to rehabilitative nursing, prosthetics, geriatric care, and rehabilitation therapy, making it a key area of sustained focus for Danlu Capital. The ZD Medical team is dynamic and energetic, dedicated to identifying clinical scenarios and unmet needs. Leveraging their strong capabilities in engineering and product development, they have launched multiple next-generation intelligent rehabilitation products, earning a solid reputation among end users. We are optimistic about ZD Medical’s growth potential and believe that, under the leadership of its management team, the company will emerge as a leading enterprise in the intelligent rehabilitation sector, injecting greater vitality into the industry.”

Lu Yongtao, Chairman of Hengxu Capital, stated that there is robust demand for rehabilitation medical services, supported by national policies. The digitalization and intelligent transformation of rehabilitation medicine, along with its future integration with elderly care and digital therapeutics, remain key areas of continuous focus for Hengxu Capital. ZD Medical^®The team comprises a group of idealistic and driven young professionals with a background in the integration of medicine and engineering. They possess a profound understanding of clinical needs and strong product commercialization capabilities. Hengxu Capital is highly optimistic about ZD Medical.^®Development Prospects in the Field of Rehabilitation.

Li Rui, Partner at Shunwei Capital, stated: “Currently, the rapid development of digital and intelligent technologies offers immense potential to address the shortage of high-quality supply in the rehabilitation medical industry. ZD Medical”^®By leveraging independent R&D and gaining deep insights into clinical rehabilitation needs, we have continuously launched a series of intelligent rehabilitation products featuring prominent technological innovations and superior user experience, thereby leading the development of the rehabilitation medical industry. The Shunwei team remains bullish on the long-term prospects of the rehabilitation healthcare sector and believes that, under the leadership of its highly mission-driven and innovative management team, Shanghai ZD Medical Technology Co., Ltd. will develop competitive, high-quality intelligent rehabilitation products. This will help drive the transformation and upgrading of the rehabilitation healthcare industry, ultimately benefiting a broad base of patients and healthcare providers.

ZD Medical^®After nearly eight years of technological exploration and accumulation, we have established a systematic, framework-based, multidisciplinary integrated technology platform with full independent intellectual property rights, along with a mature product R&D and innovation system.The Company’s Intelligent Rehabilitation Comprehensive Solution — ZD Smart Ark^®, covering OT and upper-limb rehabilitation solutions as well as PT and lower-limb rehabilitation solutions. The portfolio includes dozens of globally leading rehabilitation robots and intelligent hardware and software solutions, with multiple products having obtained medical device registration certificates. The company expects to launch more than ten additional innovative products to the market within the next two years.By enriching the product matrix, we provide users with more comprehensive solutions.

ZD Smart Ark^®——Intelligent Rehabilitation Integrated Solutions

Zhuodao’s core products have been deployed in the rehabilitation departments of nearly 1,000 general hospitals—including top-tier hospitals in China—as well as specialized rehabilitation hospitals. Leveraging a professional team dedicated to market promotion and customer service, we consistently provide customers across China with safe, effective, and high-quality medical device products and services. Our robot-assisted therapy system, which integrates rehabilitation treatment prescriptions, helps patients nationwide restore motor control, motor coordination, range of motion, and cognitive abilities. This approach more efficiently improves patients’ health status and quality of life, while significantly enhancing departmental operational efficiency and contributing to the standardization of healthcare delivery.

Steadfast and Far-Reaching, Accumulating Strength for a Breakthrough: Through nearly eight years of foundational work in the industry, ZD Medical^®Upholding the principle that professionals should focus on their areas of expertise with diligence and patience, we are driven by the mission to “provide innovative solutions for challenging problems in rehabilitation medicine through the power of technology.” We aim to drive overall progress in rehabilitation medicine and therapy through continuous innovation in engineering, committed to leveraging technology to restore patient function and sustain a high quality of life.

Danlu Capital is a venture capital firm dedicated to the healthcare and medical industry. Co-founded in early 2018 by Lu Qinchao, former Partner at Sequoia Capital China, and Su Zhenbo, former Managing Partner at Fenxiang Investment Management, Danlu Capital has consistently focused on the early-stage healthcare sector. It has systematically invested across multiple domains, including innovative medical technologies such as high-value consumables, in vitro diagnostic reagents, consumer healthcare, and digital health, as well as innovative drugs and novel medical services. Committed to delivering strong returns to its investors, Danlu Capital leverages capital to accelerate the R&D and commercialization of modern medical and pharmaceutical technologies, aiming to improve public health outcomes and establish itself as a trustworthy, enduring, and premier healthcare fund management company. “Climbing Upward, Danlu Is Always on the Journey.” Serving as the “shoulders” for entrepreneurs and investors alike, Danlu Capital deepens its expertise in innovative medical technologies, innovative drugs, and medical services, striving to become a trusted and highly influential healthcare venture capital institution that climbs to the pinnacle of success alongside its portfolio companies.

Hengxu Capital (AMAC Registration No.: P1070270) was established in 2019. As a private equity investment institution under SAIC Motor Financial Holdings Management Co., Ltd. (“SAIC Financial Holdings”), the financial platform of Shanghai Automotive Industry Corporation (“SAIC Motor”, 600104.SH), Hengxu Capital leverages SAIC Motor’s comprehensive industrial advantages and the efficient synergistic empowerment of SAIC Financial Holdings. It focuses on strategic emerging industries such as green mobility, mobility ecosystems, and health ecosystems, aiming to deliver sustainable and stable returns to investors while contributing to the development of SAIC Motor’s innovative industrial chain and the enhancement of its mobility ecosystem. The total assets under management by Hengxu Capital have exceeded RMB 30 billion. Its investors include industry leaders, financial institutions, local governments, and state-owned enterprises. The core team possesses extensive industrial resources and rich experience in project and fund management, leading investments in dozens of high-quality companies such as CATL, Horizon Robotics, Jieqing Technology, Tongxingbao, Qingtao Energy, ChipON Microelectronics, Yihua Pharmaceutical, and Shuaike Pet Care, supporting their growth into market leaders in their respective segments.